Compare FSP & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSP | CRDL |
|---|---|---|
| Founded | 1981 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.4M | 97.3M |
| IPO Year | N/A | N/A |
| Metric | FSP | CRDL |
|---|---|---|
| Price | $0.93 | $1.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 479.0K | ★ 649.2K |
| Earning Date | 10-28-2025 | 11-13-2025 |
| Dividend Yield | ★ 4.39% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $109,497,000.00 | N/A |
| Revenue This Year | $4.36 | N/A |
| Revenue Next Year | $0.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.87 | $0.77 |
| 52 Week High | $2.09 | $1.59 |
| Indicator | FSP | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 34.42 | 48.53 |
| Support Level | $0.95 | $0.88 |
| Resistance Level | $1.01 | $1.12 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 22.48 | 58.09 |
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The company's operations include rental income from real estate leasing, interest income from secured loans made on office properties, property dispositions, and fee income from asset/property management and development. Franklin Street markets Atlanta, Dallas, Denver, Houston, and Minneapolis.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.